Exploring GLP-1 drugs as preventive therapy may still hold promise within broader strategy targeting Alzheimer’s pathways beyond amyloid, ADDF notes SAN DIEGO, Dec. 4, 2025 /PRNewswire/ — Today, Novo Nordisk presented new topline results from their Evoke and Evoke+ phase 3 trials of…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
